Breast Cancer Stamp Funds $6.7 Million in 2-Year NCI Grants

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

BETHESDA, Md-Purchasers of the US Postal Service’s breast cancer awareness stamp have funded $6.7 million in 2-year grants to support novel and innovative research into the disease. The National Cancer Institute has given grants to 31 researchers, and a 32nd grant awaits final approval.

BETHESDA, Md—Purchasers of the US Postal Service’s breast cancer awareness stamp have funded $6.7 million in 2-year grants to support novel and innovative research into the disease. The National Cancer Institute has given grants to 31 researchers, and a 32nd grant awaits final approval.

NCI has earmarked its share of money raised by the stamp sales to fund investigators who want to explore areas that are underrepresented in NCI’s research portfolio, particularly high-risk projects that have a potential for a high payoff if successful. One of the aims is to develop new methodologies and technologies that will be seeds for future discovery.

Each grant will provide $75,000 a year for 2 years. NCI expects a number of these projects to develop into mature investigations for which the researchers will seek traditional grant funding.

Recent Videos
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.